ELISA for quantitation of serum C-erbB-2 oncoprotein in breast cancer patients

Journal of Immunoassay and Immunochemistry

Volumn 23, Issue 3, 2002, Pages 293-305

  Meenakshi, A ^a   Suresh Kumar, R ^a   Siva Kumar, N ^a  

^a CANCER INSTITUTE WIA   (India)

Author keywords

Breast cancer; C erbB 2; ELISA

Indexed keywords

MONOCLONAL ANTIBODY; ONCOPROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN DOMAIN; QUANTITATIVE ANALYSIS; ADULT; BINDING COMPETITION; BLOOD; BREAST TUMOR; CALIBRATION; CASE CONTROL STUDY; FEMALE; MALE; MIDDLE AGED; STANDARD;

ADULT; BINDING, COMPETITIVE; BREAST NEOPLASMS; CALIBRATION; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 0036040551     PISSN: 15321819     EISSN: None     Source Type: Journal    
DOI: 10.1081/IAS-120013028     Document Type: Article

References (32)

1. The product of the C-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity
2. The HER-2/Neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy
3. New molecule-targeting therapy with herceptin (Trastuzumab), an Anti-HER-2 (C-erbB-2) monoclonal antibody
4. Rat MAbs to the product of the C-erbB-2 proto-oncogene for diagnosis and therapy in breast cancer
5. Perceptions of herceptin: A monoclonal antibody for the treatment of breast cancer
6. HER2 in biological fluids
7. The extracellular domain of p185/Neu is released from the surface of human breast carcinoma cells, SK-BR-3
8. Generation of monoclonal antibody CIBCgp185 Against C-erbB-2 oncoprotein and its clinical evaluation
9. Rat monoclonal antibodies to the external domain of the product of the C-erbB-2 proto-oncogene
10. Preparation of monoclonal antibodies: Strategies and procedures
11. Enzyme immunoassay of human epidermal growth factor receptor (hEGFR)
12. Protein measurement with the folin-ciocalteau reagent
13. 4
14. Determination of erbB-2 protein in breast cancer tissues by different methods. Relationships with other biological parameters
15. Assessment of HER2 status in breast cancer: Why, when and how?
16. Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER-2)
17. Elevated soluble C-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients
18. Elevated erbB-2 oncoprotein levels in pre-operative and follow up serum samples define an aggressive disease course in patients with breast cancer
19. Detection of C-erbB-2 related protein in sera from breast cancer patients
20. Serum C-erbB-2 in breast cancer patients
21. Serial serum C-erbB-2 levels in patients with breast carcinoma
22. The presence of soluble C-erbB-2 in saliva and serum among women with breast carcinoma: A preliminary study
23. Plasma C-erbB-2 levels in breast cancer patients: Prognostic significance in predicting response to chemotherapy
24. Should all breast cancers be tested for C-erbB-2?
25. Elevated serum C-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer
26. Her-2/Neu (C-erbB-2) gene and protein in breast cancer
27. Clinical application of serum tumor markers
28. Detection of C-erbB-2 related protein in sera from breast cancer patients: Relationship to ERBB2 gene amplification and C-erbB-2 protein overexpressing tumor
29. Prognostic and predictive value of C-erbB-2 overexpression in primary breast cancer alone or in combination with other prognostic markers
30. Laboratory testing for HER2/Neu in breast carcinoma: An evolving strategy to predict response to targeted therapy